Skip to main content
OpenTrials
Completed

NCT Number: NCT03870243

Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia

Principal Investigator: Mohammod Jobayer Chisti

Research Protocol Title: Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children aged 1-59 months with Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial

Proposed start date: 1st July 2018, Estimated end date: 31st December 2022

Background: Feasibility and acceptability followed by effectiveness of bubble continuous positive airway pressure (CPAP) were not evaluated in childhood severe pneumonia in developing countries at a larger scale.

Objectives:

Stages I and II

* To assess the feasibility and acceptability (not only by patients' care-givers but also by physicians and nurses) of bubble CPAP in treating childhood severe pneumonia in two tertiary hospitals in Stage I and in two district hospitals in Stage II * To record adverse events following use of bubble CPAP in these settings * To understand how much resource and time are needed to institutionalize and maintain bubble CPAP as a routine practice in the health system

Stage III:

* To determine therapeutic efficacy/effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure in children admitted to hospitals with severe pneumonia and hypoxemia * To determine therapeutic effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure & mortality in children aged 1-12 months admitted to hospitals with severe pneumonia and hypoxemia * To record adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia) encountered.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 month–59 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

Dhaka, Mohakhali, 1212, Bangladesh

About this study

Methodology:

Cluster randomized controlled clinical trial

Methodology:

  • Stages I and II: Feasibility/demonstration stage will be done as an internal pilot in 3 hospitals

a. Current treatment practice, facilities, and operational challenges will be evaluated for the introduction, clinical use and maintenance of bubble CPAP

  • Stage III: Implementation of bubble CPAP will be done in 12 hospitals a. It will be done following a cluster randomized design

Data collection-socio-demographic and clinical data will be collected using structured questionnaire by trained nurses and physicians.

Research Site:

St. Paulos Millennium Medical College, Yekatit 12 and Tikur Anbessa Specialized hospitals, 14 district hospitals

Number of Participants/Patients:

Stage I-30 children in each tertiary hospital (this stage has completed and we enrolled 49 children from two tertiary hospitals; these 49 enrolled children took double of our anticipated time {4 months}) Stage II- 20 children in each general hospital (2 general/district hospitals, we have enrolled total 40 children from this two hospitals from January 2020 to July 2020, which included COVID-19 period) Stage III-1240 children in 12 general/district hospitals (620 in bubble CPAP arm and 620 in WHO standard low flow arm; each hospital will be the cluster and 6 will be randomized to each arm)

Main Inclusion Criteria:

  • Age between 1 month and 59 months
  • Meet WHO clinical criteria for severe pneumonia with hypoxemia
  • Hypoxemia (Oxygen saturation <90% in room air)
  • Parent/guardian gives informed consent to participate in the study

Statistical Analysis:

  • STATA -14: for initial two phases descriptive analysis of level of feasibility and acceptability will be performed
  • For the phase III: We shall follow the principle of intention to treat. --Treatment failure and/or death will be analyzed using χ² or Fisher's exact tests as appropriate.
  • Primary and secondary outcomes will be compared by calculating relative risks (RRs) and their 95% confidence intervals.
  • Log-linear binomial regression will be applied to adjust for covariates to evaluate the true impact of bubble CPAP in evaluating primary and secondary outcomes and to adjust for baseline differences.
  • Continuous variables will be analyzed using the Student t-test or the Mann-Whitney test as appropriate.

Study Duration:

48 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 1 month and 59 months,
  • Meet WHO clinical criteria for severe pneumonia with hypoxemia.
  • Oxygen saturation <90% despite standard flow oxygen therapy
  • Parent/guardian gives informed consent to participate in the study

Exclusion criteria

  • Known congenital heart disease, asthma, or upper -airway obstruction
  • Tracheostomy
  • Pneumothorax
  • Needs mechanical ventilation for any specific reason as decided by the clinician

Treatment and study plan

Bubble CPAP

Device

To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia

Low flow oxygen

Device

To see the effectiveness of low flow oxygen in children with severe pneumonia

Primary outcomes

  1. For stage I and II feasibility and acceptability of bubble CPAP in two tertiary and two district hospitals will be measured in number and reported in percentage

    Time frame: 7 months

    Patient level and health professional level challenge is the outcome of phase I and II. All will be measured in number and reported in percentage. For stage I and II: Primary outcome: operational challenges that may include availability of pulse oxymetry, IV cannula, IV antibiotics, oxygen supply system and nasal catheters for treating severe pneumonia Secondary outcomes: prevalence of severe pneumonia associated hypoxemia, their treatment practices, adverse events, mortality and treatment failure

  2. For stage III: Primary outcome: Treatment failure

    Time frame: 12-18 months (Mid April 2021 to Mid October 2022)

    According to this protocol treatment failure will be declared if the following criteria are met:

    A. Presence of severe hypoxemia (SpO2<85%) at any time after at least one hour of intervention plus severe respiratory distress when the child is receiving BCPAP/LF OR, B. If the patient developed the indication of mechanical ventilation when the child is receiving BCPAP/LF OR, C. If the patient died during hospitalization OR, D. If the patient left against medical advice (LAMA) due to lack of improvement or deterioration of the child during hospitalization

    All will be measured in number and reported in percentage.

Secondary outcomes

  1. Secondary outcomes: • Death • Adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia ) encountered

    Time frame: 12-18 months (Mid April 2021 to Mid October 2022)

    All will be measured in number and reported in percentage.

Other outcomes

  1. Length of hospital stay in days

    Time frame: 12-18 months (Mid April 2021 to Mid October 2022)

    Length of hospital stay will be measured and reported in days.

  2. Incidence of nasal trauma, gastric distention, shock and air leaks in number

    Time frame: 12-18 months (Mid April 2021 to Mid October 2022)

    Incidence of nasal trauma, gastric distention, shock and air leaks will be measured in number and reported in percentage.

  3. Duration of bCPAP in hour

    Time frame: 12-18 months (Mid April 2021 to Mid October 2022)

    Duration of bCPAP will be measured and reported in hour/hours.

  4. Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage

    Time frame: 12-18 months (Mid April 2021 to Mid October 2022)

    Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage.

Sponsors and collaborators

Lead sponsor

International Centre for Diarrhoeal Disease Research, Bangladesh

Other

Collaborators

  • Armauer Hansen Research Institute, Ethiopia

Registry information

Official study title

Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Mar 12, 2019
Registry last updated
Aug 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.